The future of antivirals: Broad-spectrum inhibitors

Current Opinion in Infectious Diseases

Volumn 28, Issue 6, 2015, Pages 596-602

  Debing, Yannick ^a   Neyts, Johan ^a   Delang, Leen ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

antiviral therapy; broad spectrum antiviral agents; host targeting antivirals; immune modulation; nucleoside analogues

Indexed keywords

ANTIVIRUS AGENT; ARBIDOL; BROAD SPECTRUM ANTIVIRAL AGENT; CYCLOPHILIN INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; LIPID; NITAZOXANIDE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PROTEINASE INHIBITOR; SQUALAMINE; UNCLASSIFIED DRUG; DNA DIRECTED RNA POLYMERASE; NUCLEOSIDE; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; CALICIVIRIDAE; CORONAVIRIDAE; DRUG TARGETING; IMMUNOMODULATION; INNATE IMMUNITY; LIPID METABOLISM; NONHUMAN; PICORNAVIRIDAE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; COMMUNICABLE DISEASES, EMERGING; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; IMMUNOLOGY; PROCEDURES; RNA VIRUS; VIROLOGY; VIRUS DISEASES; VIRUS ENTRY;

ANTIVIRAL AGENTS; COMMUNICABLE DISEASES, EMERGING; DNA-DIRECTED RNA POLYMERASES; DRUG DISCOVERY; HUMANS; NUCLEOSIDES; RNA VIRUSES; VIRAL PROTEINS; VIRUS DISEASES; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84946725925     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000212     Document Type: Review

References (78)

1. De Clercq E. Antivirals: Past, present and future. Biochem Pharmacol 2013; 85:727-744.
2. Paeshuyse J, Dallmeier K, Neyts J. Ribavirin for the treatment of chronic hepatitis C virus infection: A review of the proposed mechanisms of action. Curr Opin Virol 2011; 1:590-598.
3. Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014; 370:1111-1120.
4. Pelaez A, Lyon GM, Force SD, et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 2009; 28:67-71.
5. Bausch DG, Hadi CM, Khan SH, Lertora JJL. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 2010; 51:1435-1441.
6. Moreli ML, Marques-Silva AC, Pimentel VA, da Costa VG. Effectiveness of the ribavirin in treatment of hantavirus infections in the Americas and Eurasia: A meta-analysis. Virusdisease 2014; 25:385-389.
7. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-1887.
8. Dao Thi V, Debing Y, Wu X, et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology 2015; Submitted.
9. Lee J-C, Tseng C-K, Wu Y-H, et al. Characterization of the activity of 2'-Cmethylcytidine against dengue virus replication. Antiviral Res 2015; 116:1-9.
10. Rocha-Pereira J, Jochmans D, Debing Y, et al. The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model. J Virol 2013; 87:11798-11805.
11. Goris N, De Palma A, Toussaint J-F, et al. 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res 2007; 73:161-168.
12. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100:446-454.
13. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014; 508:402-405.
14. Poordad F, Lawitz E, Gitlin N, et al. Efficacy and safety of valopicitabine in combination with pegylated interferon-alpha (pegIFN) and ribavirin (RBV) in patients with chronic hepatitis C. Hepatology 2007; 46:866A.
15. Russmann S, Grattagliano I, Portincasa P, et al. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 2006; 13:3351-3357.
16. Turner TL, Kopp BT, Paul G, et al. Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res 2014; 6:217-225.
17. Bruenn J. A structural and primary sequence comparison of the viral RNAdependent RNA polymerases. Nucleic Acids Res 2003; 31:1821-1829.
18. Merino P. Chemical Synthesis of Nucleoside Analogues. Wiley; 2013.
19. Ferrari E, Huang H-C. A novel hepatitis C virus NS5B polymerase assay of de novo initiated RNA synthesis directed from a heteropolymeric RNA template. Methods Mol Biol 2013; 1030:81-92.
20. Gong EY, Kenens H, Ivens T, et al. Expression and purification of dengue virus NS5 polymerase and development of a high-throughput enzymatic assay for screening inhibitors of dengue polymerase. Methods Mol Biol 2013; 1030:237-247.
21. Fauquet CM, Mayo MA, Maniloff J, et al. Virus taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses Virology Division, International Union of Microbiological Societies. Elsevier. 2005.
22. Patick AK, Binford SL, Brothers MA, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 1999; 43:2444-2450.
23. De Palma AM, De Palma AM, Pürstinger G, et al. Potential use of antiviral agents in polio eradication. Emerg Infect Dis 2008; 14:545-551.
24. Kim Y, Lovell S, Tiew K-C, et al. Broad-spectrum antivirals against 3C or 3CLike proteases of picornaviruses, noroviruses, and coronaviruses. J Virol 2012; 86:11754-11762.
25. Rocha-Pereira J, Nascimento MSJ, Ma Q, et al. The enterovirus protease inhibitor rupintrivir exerts cross-genotypic antinorovirus activity and clears cells from the norovirus replicon. Antimicrob Agents Chemother 2014; 58:4675-4681.
26. Kim Y, Shivanna V, Narayanan S, et al. Broad-spectrum inhibitors against 3Clike proteases of feline coronaviruses and feline caliciviruses. J Virol 2015; 89:4942-4950.
27. Mazzon M, Mercer J. Lipid interactions during virus entry and infection. Cell Microbiol 2014; 16:1493-1502.
28. Delang L, Paeshuyse J, Vliegen I, et al. Statins potentiate the in vitro antihepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009; 50:6-16.
29. Ikeda M, Abe KI, Yamada M, et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44:117-125.
30. Del Real G, Jimé nez-Baranda S, Mira E, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004; 2004:541-547.
31. Gigue. , et al. re J, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell statin compounds reduce human immunodeficiency virus type 1 replica. J Virol 2004; 78:1-5.
32. Liu S, Rodriguez AV, Tosteson MT. Role of simvastatin and methyl-b-cyclodextin on inhibition of poliovirus infection. Biochem Biophys Res Commun 2006; 347:51-59.
33. Potena L, Frascaroli G, Grigioni F, et al. Hydroxymethyl-glutaryl coenzyme A reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation 2004; 109:532-536.
34. Martnez-Gutierrez M, Castellanos JE, Gallego-Gómez JC. Statins reduce dengue virus production via decreased virion assembly. Intervirology 2011; 54:202-216.
35. Gower TL, Graham BS. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother 2001; 45:1231-1237.
36. Zhu Q, Li N, Han Q, et al. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis. Antiviral Res 2013; 98:373-379.
37. Butt AA, Yan P, Bonilla H, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology 2015; 62:365-374.
38. Blaising J, Polyak SJ, Pé cheur EI. Arbidol as a broad-spectrum antiviral: An update. Antiviral Res 2014; 107:84-94.
39. Teissier E, Zandomeneghi G, Loquet A, et al. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One 2011; 6:e15874.
40. Liu MY, Wang S, Yao WF, et al. Pharmacokinetic properties and bioequivalence of two formulations of arbidol: An open-label, single-dose, randomizedsequence, two-period crossover study in healthy chinese male volunteers. Clin Ther 2009; 31:784-792.
41. Wolf MC, Freiberg AN, Zhang T, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A 2010; 107:3157-3162.
42. Vigant F, Lee J, Hollmann A, et al. A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog 2013; 9:e1003297.
43. Vigant F, Santos NC, Lee B. Broad-spectrum antivirals against viral fusion. Nat Rev Microbiol 2015; 13:426-437.
44. Song J-M, Seong B-L. Viral membranes: An emerging antiviral target for enveloped viruses? Expert Rev Anti Infect Ther 2010; 8:635-638.
45. Zasloff M, Adams AP, Beckerman B, et al. Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential. Proc Natl Acad Sci U S A 2011; 108:15978-15983.
46. Sumioka A, Yan D, Tomita S. TARP phosphorylation regulates synaptic AMPA receptors through lipid bilayers. Neuron 2010; 66:755-767.
47. Zhang X, Rao MN, Jones SR, et al. Synthesis of squalamine utilizing a readily accessible spermidine equivalent. J Org Chem 1998; 63:8599-8603.
48. Bhargava P, Marshall JL, Dahut W, et al. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res 2001; 7:3912-3919.
49. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: A prospective randomized, double-blind, placebocontrolled study of Nitazoxanide. J Infect Dis 2001; 184:103-106.
50. Rossignol J-F. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res 2014; 110:94-103.
51. Rossignol JF, La Frazia S, Chiappa L, et al. Thiazolides, a new class of antiinfluenza molecules targeting viral hemagglutinin at the posttranslational level. J Biol Chem 2009; 284:29798-29808.
52. Elazar M, Liu M, McKenna SA, et al. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology 2009; 137:1827-1835.
53. Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2014; 14:609-618.
54. Rossignol J-F, El-Gohary YM. Nitazoxanide in the treatment of viral gastroenteritis: A randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther 2006; 24:1423-1430.
55. Rossignol J-F, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009; 136:856-862.
56. Göthel SF, Marahiel MA. Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci 1999; 55:423-436.
57. Frausto SD, Lee E, Tang H. Cyclophilins as modulators of viral replication. Viruses 2013; 5:1684-1701.
58. Davis TL, Walker JR, Campagna-Slater V, et al. Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases. PLoS Biol 2010; 8:e1000439.
59. Hopkins S, Dimassimo B, Rusnak P, et al. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol 2012; 57:47-54.
60. Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatmentnäve hepatitis C patients. Hepatology 2009; 49:1460-1468.
61. Kaul A, Stauffer S, Berger C, et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 2009; 5:e1000546.
62. Coelmont L, Hanoulle X, Chatterji U, et al. Deb025 (Alisporivir) inhibits hepatitis c virus replication by preventing a cyclophilin a induced cis-trans isomerisation in domain ii of NS5A. PLoS One 2010; 5:e13687.
63. Delang L, Vliegen I, Froeyen M, Neyts J. Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother 2011; 55:4103-4113.
64. Gamble TR, Vajdos FF, Yoo S, et al. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 1996; 87:1285-1294.
65. Chatterji U, Bobardt MD, Stanfield R, et al. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells. J Biol Chem 2005; 280:40293-40300.
66. Gallay Pa, Ptak RG, Bobardt MD, et al. Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms. Viruses 2013; 5:981-997.
67. Colgan J, Asmal M, Neagu M, et al. Cyclophilin A regulates TCR signal strength in CD4 T cells via a proline-directed conformational switch in Itk. Immunity 2004; 21:189-201.
68. Braaten D, Luban J. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J 2001; 20:1300-1309.
69. Openshaw PJM, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 2005; 18:541-555.
70. Nagy P, Pogany J. The dependence of viral RNA replication on co-opted host factors. Nat Rev Microbiol 2012; 10:137-149.
71. Goulet M-L, Olagnier D, Xu Z, et al. Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog 2013; 9:e1003298.
72. Olagnier D, Scholte FEM, Chiang C, et al. Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response. J Virol 2014; 88:4180-4194.
73. Martnez-Gil L, Ayllon J, Ortigoza MB, et al. Identification of small molecules with type I interferon inducing properties by high-throughput screening. PLoS One 2012; 7:e49049.
74. Thakur CS, Jha BK, Dong B, et al. Small-molecule activators of RNase L with broad-spectrum antiviral activity. Proc Natl Acad Sci U S A 2007; 104:9585-9590.
75. Harvey R, Brown K, Zhang Q, et al. GSK983: A novel compound with broadspectrum antiviral activity. Antiviral Res 2009; 82:1-11.
76. Diamond MS, Farzan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 2013; 13:46-57.
77. Rider TH, Zook CE, Boettcher TL, et al. Broad-spectrum antiviral therapeutics. PLoS One 2011; 6:e22572.
78. Guo C, Chen L, Mo D, et al. DRACO inhibits porcine reproductive and respiratory syndrome virus replication in vitro. Arch Virol 2015; 160:1239-1247.